Search clinical trials for: subjects with cystic fibrosis and pseudomonas aeruginosa colonization in the upper airways

Total 491739 results

University of Jena

Completed

Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization

Cystic Fibrosis | Pseudomonas Aeruginosa

Germany
Gilead Sciences

Terminated

Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria (ALPINE 2)

Cystic Fibrosis | Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization

United States, Spain, United Kingdom, Denmark, Belgium, France, Italy, Germany, Israel, Netherlands, Austria, Greece
Respirion Pharmaceuticals Pty Ltd

Recruiting

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

Pseudomonas Aeruginosa | Cystic Fibrosis Lung | Respiratory Infections, Recurrent, Chronic

United States, Australia
Armata Pharmaceuticals, Inc.

Recruiting

Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection (Tailwind)

Pseudomonas Aeruginosa | Lung Infection | Non-cystic Fibrosis Bronchiectasis

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa

Cystic Fibrosis | Bacterial Disease Carrier

United States
Armata Pharmaceuticals, Inc.
Cystic Fibrosis Foundation

Completed

Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis (SWARM-Pa)

Cystic Fibrosis | Pseudomonas Aeruginosa | Lung Infection | Pseudomonas | Lung Infection Pseudomonal

United States
University of New Mexico

Completed

Detection of Pseudomonas Aeruginosa in the Airways of Patients With CF

Cystic Fibrosis

United States
University of Jena

Unknown

Longitudinal Pathogen-colonization in Cystic Fibrosis Airways and Ability to Smell

Sinusitis | Cystic Fibrosis With Other Manifestations

Germany
Tufts Medical Center

Withdrawn

Microbiota of the Respiratory Flora in Children With Cystic Fibrosis During the First Year of Life

Cystic Fibrosis

United States
Gilead Sciences

Completed

Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways (PALS)

Cystic Fibrosis | Pseudomonas Aeruginosa

Spain, United States, Germany, France, Italy, Poland
University Hospital, Brest

Active, not recruiting

Microbial Biomarkers of EArly Pseudomonas Aeruginosa Colonization in CHildren With Cystic Fibrosis (BEACH)

Cystic Fibrosis

France
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation

Cystic Fibrosis

United States, Canada, Australia, Ireland, Germany, United Kingdom
BiomX, Inc.

Active, not recruiting

Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection

Cystic Fibrosis | Chronic Pseudomonas Aeruginosa Infection

United States, Israel, Spain, Czechia, Netherlands
Aradigm Corporation
Grifols Therapeutics LLC

Completed

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4)

Non Cystic Fibrosis Bronchiectasis

United States, Italy, Poland, United Kingdom, France, Spain, Israel, Romania, Korea, Republic of, Australia, Canada, New Zealand, Hungary, Georgia, Former Serbia and Montenegro, Peru
The Hospital for Sick Children
Unity Health Toronto

Active, not recruiting

Modulation by Sex Hormones of Inflammation and Susceptibility to Pseudomonas Aeruginosa in Cystic Fibrosis Airways

Cystic Fibrosis

Canada
Novartis Pharmaceuticals
Erasmus Medical Center; Fundacion Clinic per a la Recerca Biomédica; University... and other collaborators

Completed

Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection (iBEST-1)

Non-cystic Fibrosis Bronchiectasis

Germany, Belgium, France, United Kingdom, Spain, Italy
Insmed Incorporated

Completed

Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections

Pseudomonas Aeruginosa Infection

France, Poland, United Kingdom, Germany, Spain, Belgium, Bulgaria, Denmark, Greece, Canada, Netherlands, Hungary, Italy, Ireland, Sweden, Slovakia, Austria, Serbia
National Jewish Health

Completed

Detection of Reductions in Cystic Fibrosis Airway Inflammation While Using Aztreonam Lysine Solution

Cystic Fibrosis in Adults, Chronic Colonization With Pseudomonas Aeruginosa

United States
University of Washington
Cystic Fibrosis Foundation

Completed

A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)

Cystic Fibrosis

United States
Synspira, Inc.

Terminated

A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis

Lung Diseases | Cystic Fibrosis | Pulmonary Disease | Antibiotic Resistant Infection | Respiratory Tract Disease | Cystic Fibrosis Pulmonary Exacerbation | Lung Inflammation | Burkholderia Infections | Lung Infection | Multi-antibiotic Resistance | Pulmonary Inflammation | Lung Infection Pseudomonal | Cystic Fibrosis... and other conditions

United Kingdom
Novartis

Completed

Pharmacokinetic Evaluation of an 8 -Week Treatment With Inhaled Tobramycin

Pseudomonas Infections

Germany
Gilead Sciences

Completed

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF (AZLI CAT)

Cystic Fibrosis

United States
Zafer Soultan

Completed

The Carrier Rates of Pseudomonas Aeruginosa in Family Members of Children With Cystic Fibrosis

Cystic Fibrosis | Pseudomonas Aeruginosa

United States
University of Jena

Completed

Sino-nasal Inhalation of Colistin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization

Cystic Fibrosis | Pseudomonas Aeruginosa

Germany
Gilead Sciences

Completed

International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa (AIR-CF1)

Cystic Fibrosis

United States, Canada, Australia, New Zealand
Gilead Sciences

Completed

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa (AIR-CF4)

Cystic Fibrosis | Pseudomonas Aeruginosa | Lung Infection

United States, Australia, Canada
University Hospital Tuebingen

Completed

Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo

Cystic Fibrosis | Infection | Pseudomonas Aeruginosa

Germany
Centre Hospitalier Intercommunal Creteil
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Comparison of Two Antibiotic Regimens for the Treatment of Early Airways Infection With PA in Adults With Bronchiectasis (ANTEIPA)

Bronchiectasis

France
Clarametyx Biosciences, Inc.

Recruiting

A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis

Cystic Fibrosis | Persistent Infection

United States
Sunshine Coast Hospital and Health Service
The Prince Charles Hospital; Mater

Not yet recruiting

Ceftolozane/Tazobactam Continuous Infusion for Infective Exacerbations of Cystic Fibrosis and Bronchiectasis (CERTAIN)

Bronchiectasis | Cystic Fibrosis | Pseudomonas Aeruginosa | Burkholderia Cepacia Infection
Arcturus Therapeutics, Inc.
Novotech CRO

Recruiting

Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects and Adults With Cystic Fibrosis.

Cystic Fibrosis

New Zealand
Aridis Pharmaceuticals, Inc.

Recruiting

SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects

Cystic Fibrosis

United States
Cliniques universitaires Saint-Luc- Université...

Recruiting

Implementation of a Non-invasive Version of the Imaging β-adrenergic-dependent Sweat Secretion Test (BUBBLE TEST)

Mucoviscidosis Involving the Lung

Belgium
Vertex Pharmaceuticals Incorporated

Active, not recruiting

Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

Cystic Fibrosis

Spain, Belgium, Netherlands, France, Canada, Germany, Sweden, Switzerland, Italy, Czechia, Portugal, Austria, Hungary, Norway, Poland
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older

Cystic Fibrosis

United States, Canada, Australia, Ireland, United Kingdom
Insmed Incorporated

Completed

Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLIT™] Amikacin) in Participants With Cystic Fibrosis (CF) Having Chronic Infections of Pseudomonas Aeruginosa

Cystic Fibrosis
Zambon SpA

Completed

Efficacy and Safety of Inhaled CMS in Bronchiectasis Subjects With Chronic P. Aeruginosa Infection. (PROMIS-I) (PROMIS-I)

Non Cystic Fibrosis Bronchiectasis

Australia, Greece, Israel, Italy, Portugal, Belgium, Germany, Netherlands, New Zealand, Spain, Switzerland, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

Long-term Safety of Lumacaftor/Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation

Cystic Fibrosis

United States, Canada
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation

Cystic Fibrosis

United States, Canada, United Kingdom, Australia, Ireland
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation

Cystic Fibrosis

Spain, Belgium, Netherlands, France, Canada, Germany, Sweden, Italy, Czechia, Switzerland, Portugal, Austria, Hungary, Norway, Poland
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Netherlands, United Kingdom, Germany, Portugal
Gazi University

Completed

Upper Extremity Exercise Capacity, Muscle Oxygenation, Balance in Patients With Cystic Fibrosis

Cystic Fibrosis

Turkey
Insmed Incorporated

Completed

Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis

Non-Cystic Fibrosis Bronchiectasis

United States, Spain, Korea, Republic of, Australia, Denmark, United Kingdom, Italy, Belgium, Singapore, Bulgaria, Germany, Netherlands, New Zealand, Poland
Vertex Pharmaceuticals Incorporated

Completed

A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

Cystic Fibrosis

Germany
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes

Cystic Fibrosis

Canada, France, Germany, United Kingdom, Israel, Australia, Spain, Netherlands, Denmark, Switzerland
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis

Cystic Fibrosis

Netherlands, United Kingdom
West Virginia University

Terminated

Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis (PIPE-CF)

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis

Cystic Fibrosis

United States, Belgium, Netherlands, Australia, Germany, Ireland, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Belgium, Netherlands
Parion Sciences
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United Kingdom, United States, France, Ireland

Search clinical trials for: subjects with cystic fibrosis and pseudomonas aeruginosa colonization in the upper airways

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations